NCT07081646 2026-03-13
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT06569147 2026-03-06
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Phase 1/2 Recruiting
NCT05145816 2026-02-17
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT06097832 2025-07-10
NEXICART-2
Nexcella Inc.
Phase 1/2 Recruiting
NCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting
NCT05839626 2025-06-12
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1/2 Terminated